Quantcast
Last updated on April 19, 2014 at 7:40 EDT

Latest Fibrin Stories

2013-07-23 08:31:28

-- Augments Fully Automated Assay Menu for the Detection of Fibrinolytic Disorders -- BEDFORD, Mass., July 23, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the HemosIL FDP assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The assay will be commercialized in countries throughout Europe, Asia, and other international markets. FDP is an immunoturbidimetric assay designed for the detection...

2012-05-02 22:22:05

GUANGZHOU, China, May 3, 2012 /PRNewswire-Asia/ -- Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. The acquisition was completed after obtaining all necessary Chinese Government approvals. Financial terms of the...

2012-03-23 02:22:37

BEIJING, March 23, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang"), recently received approval from the China State Food and Drug Administration ("SFDA") to begin clinical trials for its human fibrinogen to be used to...

2012-03-15 15:00:00

HELSINKI, Finland, March 15, 2012 /PRNewswire/ -- CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery. The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce intraoperative bleeding and, therefore, the volume of donor blood products (e.g., fresh...

2012-01-10 05:23:00

WAYNE, N.J., Jan. 10, 2012 /PRNewswire/ -- A recent study evaluating the efficacy of the SELPHYL® System was published in Archives of Facial Plastic Surgery by Drs. Anthony P. Sclafani and Steven A. McCormick.[i] The researchers set out to assess the changes in skin after injection of Selphyl, an ultrapure platelet-rich fibrin matrix (PRFM). Utilizing a small amount of the patient's own blood, the system isolates and prepares PRFM for injection back into the patient. The...

2012-01-06 05:33:00

WAYNE, N.J., Jan. 6, 2012 /PRNewswire/ -- Cascade Medical Enterprises, LLC (CME), a leading company with proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) technology for use in orthopedic therapeutic applications in soft tissue and bone repair, announced the sale of their technology to Musculoskeletal Transplant Foundation (MTF) and distribution by ConMed Linvatec for the worldwide orthopedic, dental, and wound care markets. CME has had a long collaborative US...

2011-10-06 14:16:00

BEVERLY HILLS, Calif., Oct. 6, 2011 /PRNewswire/ -- Facial Plastic Surgeon, Davis B. Nguyen, MD is pleased with this week's announcement by Baxter Pharmaceuticals that ARTISS Fibrin Sealant has been approved by the FDA for use in facelifts. Dr. Nguyen was one of seven prominent plastic surgeons in the country who, in 2010, conducted the Phase 3 clinical trials to prove the benefits of using fibrin glue in facelifts. http://www.drdavisnguyen.com/ (Photo:...

2011-05-17 18:00:00

KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases." (Logo:...

2011-03-08 06:59:00

LEIDEN, The Netherlands and SEATTLE, March 8, 2011 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps at up to 20 sites, including major U.S. and Dutch academic medical centers. Jaap Koopman, CEO of ProFibrix said: "The start of this large Phase II study in multiple surgical indications is a major milestone in the rapid...

2011-02-01 16:54:57

The findings suggest a possible novel target for the treatment of hemophilia A A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A. The findings, from a study by Scripps Research Assistant Professor Laurent O. Mosnier, were published in a recent edition of...